Our prior research has confirmed that ARID1A functions as the tumor suppressor of LUAD, and the absence of ARID1A activity has contributed to metastasis and resistance to first generation EGFR-TKI [7–9]. The gene discussed is ARID1A; the disease is neoplasm.